Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 5, 2002, Pages 689-697

  MacKenzie, Fiona M ^a   Greig, Paul ^a   Morrison, Donald ^b   Edwards, Giles ^b   Gould, Ian M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; METICILLIN; PHOSPHOGLYCERATE KINASE; TEICOPLANIN; VANCOMYCIN;

AGAR MEDIUM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CHROMOSOME VARIANT; CONTROLLED STUDY; GENE OVEREXPRESSION; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; PROTEIN ANALYSIS; PROTEOMICS; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS; TRANSMISSION ELECTRON MICROSCOPY; UNITED KINGDOM; ANTIBIOTIC RESISTANCE; BLOOD; CULTURE MEDIUM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICS;

BLOOD; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; SCOTLAND; STAPHYLOCOCCUS AUREUS; TEICOPLANIN;

EID: 0036849666     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf191     Document Type: Article

References (56)

1. Jarvis, W. R. (1998). Epidemiology, appropriateness, and cost of vancomycin use. Clinical Infectious Diseases 26, 1200-3.
2. Ena, J., Dick, R. W., Jones, R. N. & Wenzel, R. P. (1993). The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. Journal of the American Medical Association 269, 598-602.
3. Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S. et al. (1997). Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670-3.
4. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. & Tenover, F. C. (1997). Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40, 135-6.
5. Centers for Disease Control and Prevention. (1997). Staphylococcus aureus with reduced susceptibility to vancomycin - United States. Morbidity and Mortality Weekly Report 46, 765-6.
6. Ploy, M. C., Grelaud, C., Martin, C., de Lumley, L. & Denis, F. (1998). First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351, 1212.
7. Howe, R. A., Bowker, K. E., Walsh, T. R., Feest, T. G. & MacGowan, A. P. (1998). Vancomycin resistant Staphylococcus aureus. Lancet 351, 602.
8. Marchese, A., Balistreri, E., Tonoli, E., Debbia, E. A. & Schito, G. C. (2000). Heterogeneous vancomycin resistance in methicillin resistant Staphylococcus aureus strains isolated in a large Italian hospital. Journal of Clinical Microbiology 38, 866-9.
9. Bierbaum, G., Fuchs, K., Lenz, W., Szekat, C. & Sahl, H.-G. (1999). Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. European Journal of Microbiology and Infectious Diseases 18, 691-6.
10. Guerin, F., Buu-Hoi, A., Mainardi, J.-L., Kac, G., Colardelle, N., Vaupre, S. et al. (2000). Outbreak of methicillin resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. Journal of Clinical Microbiology 38, 2985-8.
11. Cercenado, E., Guinea, J., Garcia-Garrote, F., Cuevas, O. & Bouza, E. (2000). Methicillin-susceptible (MS) Staphylococcus aureus (SA) with reduced susceptibility to glycopeptides in a Spanish hospital. In Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 1781, p. 106. American Society for Microbiology, Washington, DC, USA.
12. Heym, B., Jurand, C., Armand-Lefevre, L. & Nicolas-Chanoine, M. H. (2000). Outbreak of methicillin resistant Staphylococcus aureus (MRSA) with reduced glycoptide susceptibility (GISA) in two surgery wards and in an intensive care unit (ICU) of a French hospital. In Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 723, p. 409. American Society for Microbiology, Washington, DC, USA.
13. Denis, O., Nonhoff, C., Bobin-Dubreux, S., Byl, B., Knoop, C., Etienne, J. et al. (2000). Emergence of methicillin resistant Staphylococcus aureus (MRSA) with decreased susceptibility to vancomycin in a Belgian hospital. In Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 1779, p. 106. American Society for Microbiology, Washington, DC, USA.
14. Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A. et al. (1998). Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. Journal of Clinical Microbiology 36, 1020-7.
15. Tenover, F. C. (2000). VRSA, VISA and GISA: the dilemma behind the name game. Clinical Microbiology Newsletter 22, 49-53.
16. Hiramatsu, K. (1998). Vancomycin resistance in staphylococci. Drug Resistance Updates 1, 135-50.
17. Hospital Infection Control Policies Advisory Committee (HICPAC). (1995). Recommendations for preventing the spread of vancomycin resistance. Infection Control and Hospital Epidemiology 16, 105-13.
18. Kaatz, G. W., Seo, S. M., Dorman, J. & Lerner, S. A. (1990). Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. Journal of Infectious Diseases 162, 103-8.
19. Shlaes, D. M., Shlaes, J. H., Vincent, S., Etter, L., Fey, P. D. & Goering, R. V. (1993). Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrobial Agents and Chemotherapy 37, 2432-7.
20. Brunet, F., Vedel, G., Dreyfus, F., Vaxelaire, J. F., Giraud. T., Schremmer, B. et al (1990). Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. European Journal of Clinical Microbiology and Infectious Diseases 9, 145-7.
21. Mainardi, J. L., Shlaes, D. M., Goering, R. V., Shlaes, J. H., Acar, J. F. & Goldstein, F. W. (1995). Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. Journal of Infectious Diseases 171, 1646-50.
22. Walsh, T. R., Howe, R. A., Wootton, M., Bennett, P. M. & MacGowan, A. P. (2001). Detection of glycopeptide resistance in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 47, 357-8.
23. Gould, I. M., Wilson, D., Milne, K., Paterson, A., Golder, D. & Russell, D. (1991). Interaction of imipenem with erythromycin and tetracycline assessed by microdilution checkerboard techniques. Antimicrobial Agents and Chemotherapy 35, 2407-9.
24. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA.
25. Bannerman, T. L., Hancock, G. A., Tenover, F. C. & Miller, J. M. (1995). Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. Journal of Clinical Microbiology 33, 551-5.
26. Leonard, R. B., Mayer, J., Sasser, M., Woods, M. L., Mooney, B. R., Brinton, B. G. et al. (1995). Comparison of MIDI Sherlock system and pulse-field gel electrophoresis in characterizing strains of methicillin-resistant Staphylococcus aureus from a recent hospital outbreak. Journal of Clinical Microbiology 33, 2723-7.
27. Bignardi, G. E., Woodford, N., Chapman, A., Johnson, A. P. & Speller, D. C. (1996). Detection of the mec-A gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillin resistance. Journal of Antimicrobial Chemotherapy 37, 53-63.
28. Brakstad, O. D., Aasbakk, K. & Maeland, J. A. (1992). Detection of Staphylococcus aureus by polymerase chain reaction amplification of the nuc gene. Journal of Clinical Microbiology 30, 1654-60.
29. Kobayashi, N., Wu, H., Kojima, K., Taniguchi, K., Urasawa, S., Uehara, N. et al. (1994). Detection of mecA, femA, and femB genes in clinical strains of staphylococci using polymerase chain reaction. Epidemiology and Infection 3, 259-66.
30. Marchese, A., Balistreri, G., Tonoli, E., Debbia, E. A. & Schito, G. C. (2000). Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. Journal of Clinical Microbiology 38, 866-9.
31. Sieradzki, K., Roberts, R., Haber, S. & Tomasz, A. (1999). The development of vancomycin resistance in a patient with MRSA infection. New England Journal of Medicine 340, 517-23.
32. Tomasz, A., Jamieson, J. & Ottolenghi, E. (1964). The fine structure of Diplococcus pneumoniae. Journal of Cell Biology 22, 453-67.
33. Cash, P., Argo, E., Ford, L., Lawrie, L. & McKenzie, H. (1999). A proteomic analysis of erythromycin resistance in Streptococcus pneumoniae. Electrophoresis 20, 2259-68.
34. Cash, P. (2000). Proteomics in medical microbiology. Electophoresis 21, 1187-201.
35. Edwards, G. F. S., Cosgrove, B., Morrison, D. & Gemmell, C. G. (2000). MRSA in Scotland (1997-99) - A Reference Laboratory Perspective. In Abstracts and Proceedings of the Ninth International Symposium on Staphylococci and Staphylococcal Infections, Kolding, Denmark, 2000. Abstract 163, p. 25.
36. Anon. (2000). MRSA with intermediate resistance to teicoplanin. Communicable Disease Report 10, 99, 102.
37. Vedel, G., Leruez, M., Lemann, F., Hraoui, E. & Ratovohery, D. (1990). Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. European Journal of Clinical Microbiology and Infectious Diseases 9, 820-2.
38. Fitch, L. & Johnson, A. P. (1998). Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 41, 578.
39. Hasan, I. A. Chadwick, P. R. & Johnston, A. P. (2001). Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) with a reduced susceptibility to teicoplanin in Northwest England. Journal of Antimicrobial Chemotherapy 48, 454-5.
40. Wootton, M., Howe, R. A., Hillman, R., Bennett, P. M. & MacGowan, A. P. (2001). A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. Journal of Antimicrobial Chemotherapy 47, 399-403.
41. Walsh, T. R., Bolmstrom, A., Qwarnstrom, A., Ho, P., Wootton, M., Howe, R. et al. (2001). Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. Journal of Clinical Microbiology 39, 2439-44.
42. Geisel, R., Schmitz, F.-J., Thomas, L., Berns, G., Zetzche, O., Ulrich, B. et al. (1999). Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area. Journal of Antimicrobial Chemotherapy 43, 846-8.
43. Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E. & Tenover, F. C. (1999). Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. Journal of Clinical Microbiology 37, 3590-3.
44. Gould, I. M. (2000). Towards a common susceptibility testing method? Journal of Antimicrobial Chemotherapy 45, 757-62.
45. MacGowan, A. P. and Wise, R. (2001). Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 17-28.
46. Chadwick, P. R. & Wooster, S. L. (2000). Glycopeptide resistance in Staphylococcus aureus. Journal of Infection 40, 211-7.
47. Centers for Disease Control and Prevention. (1997). Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. Morbidity and Mortality Weekly Report 46, 626-8, 635-6.
48. Auken, H. M., Warner, M., Ganner, M., Johnson, A. P., Richardson, J. F. & Cookson, B. D. (2000). Twenty months of screening for glycopeptide intermediate Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 46, 639-40.
49. Steward, C. D., Carson, L. A., Hil, B. C. & Tenover, F. C. (2000). Comparison of PFGE fingerprints of MRSA isolates with varying susceptibilities to vancomycin. Infection Control and Hospital Epidemiology. In Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, GA, 2000. Poster P-W2-39, p. 165.
50. dos Santos Soares, M. J., da Silva-Carvalho, M. C., Ferreira-Carvaljo, B. T. & Figueredo, A. M. S. (2000). Spread of methicillin-resistant Staphylococcus aureus belonging to the Brazilian epidemic clone in a general hospital and emergence of heterogeneous resistance to glycopeptide antibiotics among these isolates. Journal of Hospital Infection 44, 301-8.
51. Daum, R. S., Gupta, S., Sabbagh, R. & Milewski, W. M. (1992). Characterization of Staphylococcus aureus with decreased suceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. Journal of Infectious Diseases 166, 1066-72.
52. Leive, L. L. & Davis, B. D. (1980). Cell envelope; spores. In Microbiology - Including Immunology and Molecular Genetics, 3rd edn (Davis, B. D., Dulbecco, R., Elsen, H. N. & Ginsberg, H. S., Eds), pp. 71-110. Harper & Row, Philadelphia, PA, USA.
53. Henze, U. U., Roos, M. & Berger-Bachi, B. (1996). Effects of penicillin-binding protein 4 overproduction in Staphylococcus aureus. Microbial Drug Resistance 2, 103-9.
54. Sieradzki, K., Pinho, K. & Tomasz, M. (1999). Inactivated pbp-4 in highly glycopeptide resistant laboratory mutants of Staphylococcus aureus. Journal of Biological Chemistry 274, 18942-6.
55. Berger-Bächi, B., Strässle, A. & Kayser, F. H. (1986). Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. European Journal of Clinical Microbiology and Infectious Diseases 5, 697-701.
56. Tomasz, A., Drugeon, H. B., de Lencastre, H. M., Jabes, D., McDougal, L. & Bille, J. (1989). New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the pbp2a gene and contain normal penicillin-binding proteins with modified penicillin binding capacity. Antimicrobial Agents and Chemotherapy 33, 1869-1874.